SpineX Develops Non-Invasive Spinal Cord Stimulation Devices for Neurogenic Bladder and Cerebral Palsy

SpineX develops non-invasive spinal cord stimulation devices SCONE and SCiP for neurogenic bladder and cerebral palsy, offering a promising alternative to invasive treatments and improving patients' quality of life.

author-image
Trim Correspondents
New Update
SpineX Develops Non-Invasive Spinal Cord Stimulation Devices for Neurogenic Bladder and Cerebral Palsy

SpineX Develops Non-Invasive Spinal Cord Stimulation Devices for Neurogenic Bladder and Cerebral Palsy

SpineX, an Indian American-run MedTech company, has developed two non-invasive spinal cord stimulation devices, SCONE for adults with neurogenic bladder and SCiP for children with cerebral palsy. The devices are currently undergoing clinical trials and regulatory approval in the United States and India as of April 2024.

Both SCONE and SCiP are based on spinal cord stimulation technology, which involves placing electrodes near the spinal cord to deliver impulses and improve communication between the brain, spinal cord, and muscles. SCONE is a small, battery-powered device the size of a pager that can be used at home by adults, while SCiP uses a lower current to be suitable for children.

Why this matters: SpineX's novel bioelectric approach offers a non-invasive alternative to treat spinal cord-related conditions, potentially providing new hope for managing difficult neurological disorders. The devices' home-based treatment allows for ongoing therapy without frequent clinic visits, which could significantly improve patients' quality of life.

The devices are designed for home use, with an AI-powered companion app to monitor and optimize the therapy. SpineX's founder, Parag Gad, a biomedical engineer with over 15 years of experience in preclinical and clinical research, stated that the devices are classified as having a non-significant risk and are expected to provide functional improvements for patients without the side effects of medications.

Multiple clinical studies are underway to validate the effectiveness and safety of the SCONE and SCiP systems, with early results showing promising improvements in functionality. SpineX is working with the FDA in the United States and CDSCO in India to obtain simultaneous regulatory clearance in both countries.

"The devices are not one-size-fits-all and require customization by healthcare professionals based on the patient's needs," Gad explained. Further research is still needed to fully realize the potential of this 'hearing aid for the spine' approach in managing spinal cord-related conditions non-invasively.

Key Takeaways

  • SpineX develops non-invasive spinal cord stimulation devices SCONE and SCiP.
  • Devices use electrodes to improve brain-spinal cord-muscle communication for neurological conditions.
  • Devices are designed for home use with AI-powered companion apps for monitoring.
  • Clinical trials underway to validate effectiveness and safety of SCONE and SCiP.
  • Devices require customization by healthcare professionals based on patient needs.